Literature DB >> 16162622

Spectrum of cardiac abnormalities associated with long QT in stroke survivors.

K Y K Wong1, S McSwiggan, N S J Kennedy, S Y S Wong, A Gavin, R S MacWalter, A D Struthers.   

Abstract

OBJECTIVES: To find out what spectrum of cardiac abnormalities are found in those stroke survivors who can be deemed to be at high cardiac risk by their having long QT.
METHODS: 202 patients with good recovery from a cerebrovascular event occurring at least one month previously were recruited into a prospective epidemiological study. These stroke survivors underwent a battery of cardiac investigations including 12 lead ECG, echocardiography, myocardial perfusion scanning, and heart rate variability assessment. The ECGs were digitised by a single observer blinded to the blood pressure and other investigations of the patients. The maximum heart rate corrected QT interval (QTc max) in the 12 lead ECG was derived by Bazett's formula.
RESULTS: Prolonged QTc max significantly correlated with increasing blood pressure, left ventricular mass index, and depressed heart rate variability. As the number of cardiac abnormalities increased, QTc max became more prolonged.
CONCLUSIONS: Long QT is significantly associated with left ventricular mass index even after adjustment for both systolic and diastolic blood pressures. Long QT was also associated with the total cardiac disease burden. These two observations may explain why stroke survivors with long QTc max were at greater risk of cardiac death.

Entities:  

Mesh:

Year:  2005        PMID: 16162622      PMCID: PMC1769139          DOI: 10.1136/hrt.2004.045187

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  18 in total

1.  Midwall mechanics are improved after regression of hypertensive left ventricular hypertrophy and normalization of chamber geometry.

Authors:  S Perlini; M L Muiesan; C Cuspidi; L Sampieri; B Trimarco; G P Aurigemma; E Agabiti-Rosei; G Mancia
Journal:  Circulation       Date:  2001-02-06       Impact factor: 29.690

Review 2.  Should we add screening for and treating left ventricular hypertrophy to the management of all patients needing secondary prevention of cardiovascular disease?

Authors:  A D Struthers; J Davies
Journal:  QJM       Date:  2003-06

3.  Long-term beta-blocker therapy improves autonomic nervous regulation in advanced congestive heart failure: a longitudinal heart rate variability study.

Authors:  J L Lin; H L Chan; C C Du; I N Lin; C W Lai; K T Lin; C P Wu; Y Z Tseng; W P Lien
Journal:  Am Heart J       Date:  1999-04       Impact factor: 4.749

Review 4.  Measurement of heart rate variability: a clinical tool or a research toy?

Authors:  H V Huikuri; T Mäkikallio; K E Airaksinen; R Mitrani; A Castellanos; R J Myerburg
Journal:  J Am Coll Cardiol       Date:  1999-12       Impact factor: 24.094

5.  Physical activity attenuates the effect of increased left ventricular mass on the risk of ischemic stroke: The Northern Manhattan Stroke Study.

Authors:  Carlos J Rodriguez; Ralph L Sacco; Robert R Sciacca; Bernadette Boden-Albala; Shunichi Homma; Marco R Di Tullio
Journal:  J Am Coll Cardiol       Date:  2002-05-01       Impact factor: 24.094

6.  Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure.

Authors:  A Mortara; M T La Rovere; G D Pinna; R Maestri; S Capomolla; F Cobelli
Journal:  J Am Coll Cardiol       Date:  2000-11-01       Impact factor: 24.094

7.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

8.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.

Authors: 
Journal:  Lancet       Date:  2001-09-29       Impact factor: 79.321

9.  Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.

Authors:  J Mathew; P Sleight; E Lonn; D Johnstone; J Pogue; Q Yi; J Bosch; B Sussex; J Probstfield; S Yusuf
Journal:  Circulation       Date:  2001-10-02       Impact factor: 29.690

10.  Long QTc predicts future cardiac death in stroke survivors.

Authors:  K Y K Wong; R S Mac Walter; D Douglas; H W Fraser; S A Ogston; A D Struthers
Journal:  Heart       Date:  2003-04       Impact factor: 5.994

View more
  3 in total

1.  Long-term blockade of L/N-type Ca(2+) channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart.

Authors:  A Takahara; Y Nakamura; H Wagatsuma; S Aritomi; A Nakayama; Y Satoh; Y Akie; A Sugiyama
Journal:  Br J Pharmacol       Date:  2009-09-28       Impact factor: 8.739

2.  QT peak prolongation is not associated with left ventricular hypertrophy in teenage professional football players.

Authors:  Samir Alchaghouri; Kenneth Y K Wong; Raphael A Perry; David R Ramsdale; John D Somauroo; Jason R Pyatt
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

3.  Prognostic Significance of Prolonged Corrected QT Interval in Acute Ischemic Stroke.

Authors:  Sung-Ho Ahn; Ji-Sung Lee; Young-Hak Kim; Mi-Sook Yun; Jung-Hee Han; Soo-Young Kim; Min-Gyu Park; Kyung-Pil Park; Dong-Wha Kang; Jong S Kim; Sun U Kwon
Journal:  Front Neurol       Date:  2021-12-20       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.